Morgan Stanley analyst Tejas Savant maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $4 to $2.
- Headlines
- Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2
Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
09:39
Large cap block orders have a net outflow of over 10 billion.
09:39
The US dollar just fell below the 7.2900 yuan mark against the offshore renminbi, currently reported at 7.2898 yuan, down 0.13% during the day; the US dollar against the onshore renminbi is currently reported at 7.2805 yuan, down 0.09% during the day.
09:38
Countdown 1 day - Mao Ge Ping's IPO subscription will close at 9 a.m. on December 5.